Aspirin has shown a significant reduction in death rates from cancer, heart disease, and stroke, but its benefits are most pronounced when taken earlier in life. While starting aspirin later may lead to increased bleeding risks without substantial benefits, those with a family history of certain cancers could see a 50% reduction by taking a daily low dose. The quest for a new generation of aspirin that retains its anti-inflammatory properties without the bleeding risks remains unfulfilled, largely due to the lack of pharmaceutical interest.
